Discovery and development of broad spectrum anti-flaviviral drugs

广谱抗黄病毒药物的发现和开发

• 批准号: 8661106
• 负责人: DANIEL A ENGEL
• 金额: $ 82.68万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8661106
• 关键词: Address; Animal Model; Animals; Antiviral Agents; Antiviral Therapy; Arthropods; Binding; Binding Proteins; Biochemistry; Biological Models; Categories; Cell Culture Techniques; Cells; Chemicals; Clinical Drug Development; Country; Culicidae; Dengue; Dengue Virus; Development; Disease; Drug Kinetics; Drug Targeting; Encephalitis; Flavivirus; Genome; Goals; Health; Human; In Vitro; Individual; Infection; Integration Host Factors; Laboratories; Lead; Libraries; Mass Spectrum Analysis; Maximum Tolerated Dose; Methodology; Methods; Mining; Modeling; Molecular Virology; Mus; National Institute of Allergy and Infectious Disease; North America; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacology; Protein Binding; Proteins; Proteome; Public Health; Purines; RNA Interference; Readiness; Research Personnel; Risk; Staging; Technology; Testing; Therapeutic; Time; United States National Institutes of Health; Universities; Vaccines; Virginia; Virus; Virus Diseases; Virus Replication; West Nile virus; Work; Yeasts; Yellow Fever; Yellow fever virus; arm; base; biodefense; cellular targeting; combat; drug discovery; high throughput screening; human disease; inhibitor/antagonist; member; mouse model; novel; pathogen; pre-clinical; prevent; programs; purine; purine analog; research clinical testing; scaffold; screening; small molecule; small molecule libraries; tissue culture

DESCRIPTION (provided by applicant): Arthropod-borne flaviviruses cause a wide range of important human diseases for which there are no specific therapies. To address this critical shortfall in preparedness to confront these emerging and re-emerging viruses, the goal of this proposal is to discover novel drug targets and develop new antiviral therapies that can be used broadly to treat a variety of flaviviral infections. A partnership of four independent academic laboratories, two at Duke Univeristy and two at the University of Virginia, will attack crucial aspects of pre- clinical drug development, as organized into the following specific aims: (1) Identification of high-quality targets for pan-flaviviral therapeutics. In this aim, three independent yet complementary approaches will be used to identify cellular targets for broad-spectrum therapies capable of treating a diverse group of flaviviral illnesses. These include genome-scale RNAi screens to identify novel host factors required for flaviviral infection, mining of the human "purinome" to find purine-binding proteins that support infection, and application of a yeast-based drug discovery platform for the identification of novel targets. (2) Chemical screens for inhibitors of flavivirus replication. Targets identified in Aim 1 will be evaluated, and a subset will subjected to small molecule library screens using proteome mining and yeast-based methodologies. Priority will be given to compounds showing broad-spectrum activity including efficacy against mosquito-borne flaviviruses. (3) SAR and medicinal chemistry to define pan anti-flaviviral inhibitors. Up to six independent medicinal chemistry programs will be carried forward based on the most attractive products of the screens from Aim 2. Lead compounds will be optimized for potency of in vitro binding and efficacy in tissue culture models. (4) Pre-clinical testing. Established mouse models of YFV and WNV infection and newly established models of DENV infection will be used for maximum tolerated dose and initial pharmacological and efficacy studies. Flaviviruses are an emerging threat to public health in the US, a current risk to our armed forces and other citizens deployed around the world, and a major problem globally. At this time there is little that can be done to prevent or treat the majority of flaviviral infections and therefore development of broad-spectrum anti-flaviviral drugs is of crucial importance.

描述（由申请人提供）：节肢动物传播的黄病毒引起一系列重要的人类疾病，目前尚无特异性治疗方法。为了解决在应对这些新出现和再出现的病毒方面的严重不足，本提案的目标是发现新的药物靶点并开发新的抗病毒疗法，可广泛用于治疗各种黄病毒感染。一个由四个独立学术实验室组成的伙伴关系，两个在杜克大学，两个在弗吉尼亚大学，将研究临床前药物开发的关键方面，组织成以下具体目标：(1)确定泛黄病毒治疗的高质量靶点。在这个目标中，三种独立但互补的方法将被用来确定能够治疗多种黄病毒疾病的广谱疗法的细胞靶点。这些包括基因组规模的RNAi筛选，以确定黄病毒感染所需的新宿主因子，挖掘人类“嘌呤组”，以发现支持感染的嘌呤结合蛋白，以及应用基于酵母的药物发现平台来识别新靶点。(2)黄病毒复制抑制剂的化学筛选。将对Aim 1中确定的靶点进行评估，并使用蛋白质组挖掘和基于酵母的方法进行小分子文库筛选。将优先考虑具有广谱活性的化合物，包括对蚊媒黄病毒有效的化合物。(3)用SAR和药物化学方法定义泛类抗黄病毒抑制剂。根据Aim 2筛选中最具吸引力的产品，将开展多达6个独立的药物化学项目。将优化先导化合物的体外结合效力和组织培养模型的效果。(4)临床前试验。已建立的YFV和WNV感染小鼠模型以及新建立的DENV感染模型将用于最大耐受剂量和初始药理学和疗效研究。黄病毒是对美国公共卫生的新威胁，是目前对我们的武装部队和部署在世界各地的其他公民的威胁，也是全球的一个主要问题。在这个时候，几乎没有什么可以预防或治疗大多数黄病毒感染，因此开发广谱抗黄病毒药物至关重要。

项目成果

Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness.

• DOI: 10.1126/science.aab3369
• 发表时间: 2015-10-09
• 期刊: Science (New York, N.Y.)
• 作者: Manokaran G;Finol E;Wang C;Gunaratne J;Bahl J;Ong EZ;Tan HC;Sessions OM;Ward AM;Gubler DJ;Harris E;Garcia-Blanco MA;Ooi EE
• 通讯作者: Ooi EE